Neurelis Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
185
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$150M
- Investors
-
8
Neurelis General Information
Description
Operator of neuroscience-based therapeutics intended to address unmet medical needs in epilepsy and rare central nervous system disorders. The company offers targeted drug delivery technologies applicable to a range of molecules, including proteins, peptides, and small molecules, enabling healthcare providers to improve treatment outcomes and enhance patient care.
Contact Information
Website
www.neurelis.comCorporate Office
- 3430 Carmel Mountain Road
- Suite 300
- San Diego, CA 92121
- United States
Corporate Office
- 3430 Carmel Mountain Road
- Suite 300
- San Diego, CA 92121
- United States
Neurelis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Debt - General | 11-Aug-2021 | $150M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series D) | 05-Mar-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 06-Oct-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 30-Dec-2016 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series A) | 02-Jul-2015 | Completed | Product Development | |||
| 2. Merger/Acquisition | 11-Jul-2014 | $8.75M | Cancelled | Startup | ||
| 1. Seed Round | 30-Sep-2011 | $4.5M | $4.5M | Completed | Startup |
Neurelis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 19,815,059 | $0.000100 | 8% | $0.76 | $0.76 | 1x | $0.76 | 11.46% |
| Series A | 37,744,121 | $0.000100 | 8% | $0.47 | $0.47 | 1x | $0.47 | 21.83% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neurelis Comparisons
Industry
Financing
Details
Neurelis Competitors (26)
One of Neurelis’s 26 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| Ovid Therapeutics | Formerly VC-backed | New York, NY | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
Neurelis Patents
Neurelis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193385-A1 | Treatment of early status epilepticus and prolonged seizures with intranasal diazepam | Pending | 13-Mar-2025 | ||
| US-20250281479-A1 | Treatment of cavernous angiomas with a 4-substituted piperidine derivative | Pending | 07-Mar-2024 | ||
| WO-2025189104-A1 | Treatment of cavernous angiomas with a 4-substituted piperidine derivative | Pending | 07-Mar-2024 | ||
| WO-2025189104-A8 | Treatment of cavernous angiomas with a 4-substituted piperidine derivative | Pending | 07-Mar-2024 | ||
| WO-2025188992-A1 | Oral film for rapid active delivery | Pending | 06-Mar-2024 | A61K31/551 |
Neurelis Signals
Neurelis Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Philos & Partners | Family Office | Minority | ||
| China Medical System Holdings | Corporation | Minority |
Neurelis Acquisitions (1)
Neurelis’s most recent deal was a Merger/Acquisition with Aegis Therapeutics. The deal was made on 03-Dec-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aegis Therapeutics | 03-Dec-2018 | Merger/Acquisition | Drug Delivery |
Neurelis FAQs
-
When was Neurelis founded?
Neurelis was founded in 2007.
-
Where is Neurelis headquartered?
Neurelis is headquartered in San Diego, CA.
-
What is the size of Neurelis?
Neurelis has 185 total employees.
-
What industry is Neurelis in?
Neurelis’s primary industry is Drug Discovery.
-
Is Neurelis a private or public company?
Neurelis is a Private company.
-
What is Neurelis’s current revenue?
The current revenue for Neurelis is .
-
How much funding has Neurelis raised over time?
Neurelis has raised $382M.
-
Who are Neurelis’s investors?
Cormorant Asset Management, Decheng Capital, OrbiMed, Philos & Partners, and China Medical System Holdings are 5 of 8 investors who have invested in Neurelis.
-
Who are Neurelis’s competitors?
NeuroNascent, Neurogene, Ovid Therapeutics, Minerva Neurosciences, and Cognition Therapeutics are some of the 26 competitors of Neurelis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process